Aripiprazole (Abilify Maintena) vs Aripiprazole lauroxil (Aristada)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole (Abilify Maintena)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00706654 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.

Reported efficacy

Mean change from baseline to endpoint(10th week)in PANSS Total Score. (1st,2nd,4th,6th,8th,10th,12th week): LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin (met)

Result source: NCT03172871

Aripiprazole lauroxil (Aristada)

Marketed by Alkermes plc

Approved in Schizophreniasmall molecule
Reliable signal

NCT01469039 · Phase 3 · completed

The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).

Reported efficacy

The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)

Result source: NCT01469039

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole (Abilify Maintena)Aripiprazole lauroxil (Aristada)
PANSS total, change-26.8 vs -11.7−15.1 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -23.7 vs -9.7 400/300 mg · wk 8 · n 162 · Phase 3 · primary NCT01663532
  • -21.5 vs -10.3 400/300 mg · wk 6 · n 162 · Phase 3 · primary NCT01663532
  • -19 vs -9.8 400/300 mg · wk 4 · n 162 · Phase 3 · primary NCT01663532
  • -15.2 vs -8.3 400/300 mg · wk 2 · n 162 · Phase 3 · primary NCT01663532
  • -8.9 vs -5 400/300 mg · wk 1 · n 162 · Phase 3 · primary NCT01663532
  • -33.6 vs -34.8 wk 10 · Phase 3 · primary NCT03172871
-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039
CGI-S, change-1.4 vs -0.6−0.8 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -1.3 vs -0.6 400/300 mg · wk 8 · n 162 · Phase 3 · secondary NCT01663532
  • -1.2 vs -0.5 400/300 mg · wk 6 · n 162 · Phase 3 · secondary NCT01663532
  • -1 vs -0.4 400/300 mg · wk 4 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.4 400/300 mg · wk 2 · n 162 · Phase 3 · secondary NCT01663532
  • -0.4 vs -0.2 400/300 mg · wk 1 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456
PANSS response37% vs 14.3%+22.7 vs placebo400/300 mg · wk 10 · n 162NCT01663532—Not reported
PSP, change12.3 vs 5.2+7.1 vs placebo400/300 mg · wk 10 · n 139NCT01663532—Not reported
Relapse (% of patients)10% vs 39.6%−29.6 vs placebowk 52 · n 269NCT00705783—Not reported

PANSS total, change

Aripiprazole (Abilify Maintena)
-26.8 vs -11.7−15.1 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -23.7 vs -9.7 400/300 mg · wk 8 · n 162 · Phase 3 · primary NCT01663532
  • -21.5 vs -10.3 400/300 mg · wk 6 · n 162 · Phase 3 · primary NCT01663532
  • -19 vs -9.8 400/300 mg · wk 4 · n 162 · Phase 3 · primary NCT01663532
  • -15.2 vs -8.3 400/300 mg · wk 2 · n 162 · Phase 3 · primary NCT01663532
  • -8.9 vs -5 400/300 mg · wk 1 · n 162 · Phase 3 · primary NCT01663532
  • -33.6 vs -34.8 wk 10 · Phase 3 · primary NCT03172871
Aripiprazole lauroxil (Aristada)
-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039

CGI-S, change

Aripiprazole (Abilify Maintena)
-1.4 vs -0.6−0.8 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -1.3 vs -0.6 400/300 mg · wk 8 · n 162 · Phase 3 · secondary NCT01663532
  • -1.2 vs -0.5 400/300 mg · wk 6 · n 162 · Phase 3 · secondary NCT01663532
  • -1 vs -0.4 400/300 mg · wk 4 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.4 400/300 mg · wk 2 · n 162 · Phase 3 · secondary NCT01663532
  • -0.4 vs -0.2 400/300 mg · wk 1 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
Aripiprazole lauroxil (Aristada)
-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456

PANSS response

Aripiprazole (Abilify Maintena)
37% vs 14.3%+22.7 vs placebo400/300 mg · wk 10 · n 162NCT01663532
Aripiprazole lauroxil (Aristada)
—Not reported

PSP, change

Aripiprazole (Abilify Maintena)
12.3 vs 5.2+7.1 vs placebo400/300 mg · wk 10 · n 139NCT01663532
Aripiprazole lauroxil (Aristada)
—Not reported

Relapse (% of patients)

Aripiprazole (Abilify Maintena)
10% vs 39.6%−29.6 vs placebowk 52 · n 269NCT00705783
Aripiprazole lauroxil (Aristada)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Aripiprazole (Abilify Maintena): 7 of 7 rows · Aripiprazole lauroxil (Aristada): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole (Abilify Maintena)
Rows use multiple source trials
Aripiprazole lauroxil (Aristada)
Rows use multiple source trials
CGI-S
absolute change · score
No placebo or comparator arm
-0.24 score @ 52wk400/300 mg IM Depota,b,c,d
NCT00731549 · Phase 3 · registry result, not featured evidence
-0.2 scorea,b,c,d
NCT02634320 · Phase 4 · registry result, not featured evidence
2 other source trials
-0.1 scoreHigh
NCT01895452 · Phase 3 · registry result, not featured evidence
-0.1 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-3.55 score @ 52wk400/300 mg IM Depotb,c,d
NCT00731549 · Phase 3 · registry result, not featured evidence
-0.9 scoreHighe,b,c,d
NCT01895452 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.7 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
QLS Total
absolute change · score
No placebo or comparator arm
2.32 score @ 24wka,b,c,d
NCT01959035 · Phase 3 · registry result, not featured evidence
0.4 scorea,b,c,d
NCT02634320 · Phase 4 · registry result, not featured evidence
Dropout rate
—300 or 400 mgf
NCT00706654 · Phase 3
show 13 more results
—25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
44%400/300 mg
NCT01663532 · Phase 3
26.1%
NCT02360319 · Phase 4 · registry result, not featured evidence
12.5%
NCT01959035 · Phase 3 · registry result, not featured evidence
32.4%
NCT01795547 · Phase 3 · registry result, not featured evidence
39.2%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
20.6%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
11.1%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
26.3%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
6.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
35.1%882 mgg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
37.2%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.4%
NCT02634320 · Phase 4 · registry result, not featured evidence
12.4%High
NCT01895452 · Phase 3 · registry result, not featured evidence
6.2%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—300 or 400 mgf
NCT00706654 · Phase 3
show 13 more results
—25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
4.2%400/300 mg
NCT01663532 · Phase 3
—
NCT02360319 · Phase 4 · registry result, not featured evidence
5.7%
NCT01959035 · Phase 3 · registry result, not featured evidence
10.8%
NCT01795547 · Phase 3 · registry result, not featured evidence
8.1%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
2.9%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
—882 mgg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
—441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
7.3%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
1.5%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Serious AEs
5.7%300 or 400 mgf
NCT00706654 · Phase 3
show 13 more results
8.4%25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
4.1%Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
4.8%400/300 mg
NCT01663532 · Phase 3
29.1%
NCT02360319 · Phase 4 · registry result, not featured evidence
3.4%
NCT01959035 · Phase 3 · registry result, not featured evidence
8.3%
NCT01795547 · Phase 3 · registry result, not featured evidence
6.8%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
8.8%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
2.9%400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
1.9%882 mgg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
1.4%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.1%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
0%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.8%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
0%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
300 or 400 mgf
insomnia 11.7%
akathisia 10.6%
headache 9.8%
NCT00706654 · Phase 3
show 12 more results
25 or 50 mg
insomnia 13.7%
back pain 11.5%
weight decreased 9.2%
NCT00706654 · Phase 3
insomnia 10% (placebo 9%)
weight increased 9.7% (placebo 9.7%)
anxiety 5.9% (placebo 7.5%)
NCT00705783 · Phase 3 · monotherapy
400/300 mg
weight increased 16.8% (placebo 7%)
headache 14.4% (placebo 16.3%)
akathisia 11.4% (placebo 3.5%)
NCT01663532 · Phase 3
weight gain 14.4%
anxiety 12.2%
depression 10.4%
NCT02360319 · Phase 4 · registry result, not featured evidence
weight increased 6.8%
NCT01959035 · Phase 3 · registry result, not featured evidence
accidental overdose 20.8%
insomnia 11.8%
weight increased 9%
NCT01795547 · Phase 3 · registry result, not featured evidence
400/300 mg
weight increased 29.7%
akathisia 12.2%
headache 8.1%
NCT01683058 · Phase 3 · registry result, not featured evidence
400/300 mg IM Depot
headache 7.6%
nasopharyngitis 7%
anxiety 6.8%
NCT00731549 · Phase 3 · registry result, not featured evidence
400 mg
injection site pain 27.5%
weight increased 12.3%
headache 11.6%
NCT01909466 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 35.3%
headache 23.5%
akathisia 17.6%
NCT01646827 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 27.8%
headache 22.2%
akathisia 16.7%
NCT01646827 · Phase 1 · registry result, not featured evidence
400mg
injection site pain 6.7%
toothache 6.7%
blood creatine phosphokinase increased 5%
NCT01552772 · Phase 1 · registry result, not featured evidence
882 mgg
insomnia 12% (placebo 11.6%)
akathisia 11.1% (placebo 4.3%)
headache 8.7% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
441 mg
akathisia 11.6% (placebo 4.3%)
insomnia 9.7% (placebo 11.6%)
headache 8.2% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
insomnia 10.1%
weight increased 4.6%
headache 3%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
headache 6.4%
weight increased 6.4%
insomnia 2.7%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
anxiety 5.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
High
insomnia 7.1%
nasopharyngitis 4%
diarrhoea 3.1%
NCT01895452 · Phase 3 · registry result, not featured evidence
Low
diarrhoea 6.2%
nasopharyngitis 6.2%
toothache 6.2%
NCT01895452 · Phase 3 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole (Abilify Maintena)

Exacerbation 7.12% (n=265) @ 26wk300 or 400 mg
absolute value · percentage points
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
21.8% (n=131) @ 26wk25 or 50 mg
NCT00706654 · Phase 3
Time to Exacerbation NA months300 or 400 mg
time to event · months
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
NA months25 or 50 mg
NCT00706654 · Phase 3
Responder 89.8% (n=264) @ 38wk300 or 400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
75.2% (n=129) @ 38wk25 or 50 mg
NCT00706654 · Phase 3
Clinical Remission 48.8% (n=215) @ 38wk300 or 400 mg
responder rate · % of participants
No placebo or comparator arm
NCT00706654 · Phase 3
show 1 more result
59.7% (n=72) @ 38wk25 or 50 mg
NCT00706654 · Phase 3
Time to Exacerbation NA vs 6.87 placebo months @ 52wk
time to event · months
Maintenance
NCT00705783 · Phase 3 · monotherapy
Relapse 10% (n=269) vs 39.6% (n=134) placebo @ 52wk
event count · % of participants
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS 87.6% (n=267) vs 56% (n=134) placebo @ 52wk
responder rate · % of participants
Maintenance
NCT00705783 · Phase 3 · monotherapy
Clinical Remission 52.9% (n=87) vs 38.7% (n=31) placebo @ 52wk
responder rate · % of participants
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS Total 1.43 vs 11.55 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
CGI-S 0.14 vs 0.66 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS Positive Subscale 0.44 vs 4.25 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy
PANSS Negative Subscale 0.19 vs 1.55 placebo score @ 52wk
absolute change · score
Maintenance
NCT00705783 · Phase 3 · monotherapy

+ 31 further endpoints in the CSV export.

Aripiprazole lauroxil (Aristada)

PANSS Total -10 vs -19.1 placebo score @ 52wk441-441 mg
absolute change · score
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-8.3 vs -19.1 placebo score @ 52wk882-882 mg
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-5.9 vs -19.1 placebo score @ 52wk
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Positive Subscale -3.4 vs -5.8 placebo score @ 52wk441-441 mg
absolute change · score
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.3 vs -5.8 placebo score @ 52wk882-882 mg
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.8 vs -5.8 placebo score @ 52wk
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Negative Subscale -1.5 vs -4.1 placebo score @ 52wk441-441 mg
absolute change · score
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.1 vs -4.1 placebo score @ 52wk882-882 mg
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -4.1 placebo score @ 52wk
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS General Psychopathology -5.1 vs -9.2 placebo score @ 52wk441-441 mg
absolute change · score
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-4 vs -9.2 placebo score @ 52wk882-882 mg
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-2.9 vs -9.2 placebo score @ 52wk
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
BPRS Total -2.7 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify Maintena)'s landscape · Aripiprazole lauroxil (Aristada)'s landscape